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Abstract
Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a 
mild anti-resorptive agent that reduces fracture risk in the general population. Here we assessed 
the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ 
rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or 
raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal 
parameters (microCT, histology, whole bone mechanics, and material properties). Their normal 
littermates served as controls. Animals with CKD had significantly higher parathyroid hormone 
levels compared to normal controls as well as inferior structural and mechanical skeletal 
properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous 
bone volume in the rats with CKD. While it had little effect on cortical bone geometry it resulted 
in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, 
achieving levels equivalent to normal controls. Animals treated with raloxifene had superior 
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tissue-level mechanical properties as assessed by nanoindentation and higher collagen D-periodic 
spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole 
bone mechanical properties in CKD through its impact on skeletal material properties.
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chronic kidney disease; bone quality; raloxifene
INTRODUCTION
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is characterized by 
hyperphosphatemia, secondary hyperparathyroidism, and an increased risk of fractures [1–
3]. For patients with early stage CKD (estimated glomerular filtration rate greater than 30 
mL/min) and normal PTH levels, most guidelines adopt treatment recommendations for 
osteoporosis patients without CKD [3–4]. The majority of patients with osteoporosis are 
treated with anti-resorptive agents that reduce osteoclast-mediated bone loss [5]. 
Unfortunately, the complex metabolic background of CKD and a lack of clinical data in 
patients with advanced disease have limited the use of these agents.
Raloxifene is a selective estrogen receptor modulator with mild anti-resorptive properties. 
Clinical trials have shown that it effectively reduces fracture risk in patients with 
osteoporosis despite modest reductions in bone turnover and meager improvements in bone 
volume, mineralization, and BMD [6–7]. Preclinical studies indicate that raloxifene 
improves mechanical properties through its effects on bone quality [8–10]. Specifically, 
raloxifene positively affects bone toughness (the ability of bone to tolerate damage without 
fracturing). This improvement occurs in the absence of significant changes in bone mass [8–
9] and appears to be partly due to changes in bone matrix hydration [11–12]. Furthermore, 
secondary analyses of a human clinical trial have revealed beneficial renal outcomes in 
patients using raloxifene [13]. Preclinical experiments [14–15] and a small clinical study in 
dialysis patients [16] have supported these findings. Taken together, these data suggest that 
raloxifene could have beneficial effects on several consequences of CKD. The goal of the 
current work was to test the hypothesis that raloxifene would improve skeletal properties in 
an animal model of progressive CKD.
RESULTS
Mineral Metabolism
Animals with CKD had higher serum levels of BUN compared to normal littermates 
(+231%), consistent with previous data indicating the presence of late stage kidney disease 
(estimated to be 20–25% of normal kidney function) (Table 1). Serum calcium was normal, 
while phosphorus (+48%), FGF23 (+266%), and PTH levels (+1106%) were all significantly 
higher than their normal counterparts. Raloxifene-treated animals had biochemical profiles 
that were statistically indistinguishable from their untreated CKD counterparts although 
non-significant trends existed for PTH, phosphorous and FGF23.
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MicroCT
Vehicle-treated CKD animals had lower trabecular bone volume (with lower trabecular 
number and higher trabecular spacing) relative to normal animals at the proximal tibia. 
Raloxifene had normal trabecular bone volume in the proximal tibia (due to higher 
trabecular number and lower spacing than CKD animals) (Figure 1 and Table 2). In the 
vertebra, CKD animals had significantly lower trabecular bone volume (due to lower 
trabecular number and higher spacing) compared to normal controls. Raloxifene-treated 
animals had an intermediate phenotype, with BV/TV higher than vehicle-treated CKD 
animals but still lower than normal controls (Figure 1 and Table 2).
Cortical bone of the femoral midshaft was also negatively affected by CKD. CKD animals 
had lower cortical area, cortical thickness, and cross-sectional moments of inertia compared 
to normal controls (Table 2). There was no difference in cortical porosity between normal 
and vehicle-treated CKD animals. Raloxifene treatment resulted in less porosity than CKD 
animals but displayed no differences in cortical area, thickness, or moments of inertia. CKD 
animals had thinner vertebral cortices than their normal counterparts, and raloxifene animals 
were similar to vehicle-treated animals (Table 2).
Histology
Vehicle-treated CKD animals had higher trabecular bone formation rates in the tibia 
(+137%) and vertebra (+306%) compared to normal animals (Figure 2). This was a result of 
higher mineral apposition rates as well as a higher proportion of mineralizing surfaces 
(Table 3). Animals with CKD also had higher osteoclast number and percent osteoclast 
surface than their normal counterparts (Table 3). Raloxifene animals had lower bone 
formation rates compared to vehicle-treated CKD animals at both the tibia and the vertebra; 
these rates were not different from normal controls (Figure 2). Osteoclast parameters were 
similar in vehicle-treated CKD animals and their raloxifene-treated counterparts (Table 3).
Whole Bone Mechanics
Animals with CKD had lower femoral cortical bone ultimate force (−25%), stiffness 
(−22%), and energy to fracture (−23%) compared to normal animals (Figure 3 and Table 4). 
Estimated material properties revealed a significantly lower modulus of toughness in CKD 
animals (−16%) (Figure 3). Ultimate stress and elastic modulus were not different (Table 4). 
Animals treated with raloxifene displayed a higher energy to fracture compared to vehicle-
treated CKD animals accompanied by higher (though not normal) ultimate force. There was 
no effect of treatment on stiffness. There also was no effect of raloxifene treatment on 
ultimate stress or elastic modulus, but the modulus of toughness was equivalent to normal 
(Figure 3).
Vertebral compression tests revealed that CKD animals had lower ultimate force and energy 
to ultimate force but no differences in stiffness compared to normal animals (Figure 3 and 
Table 4). There also was no effect on estimated material properties of the vertebra. 
Compared to animals with CKD, raloxifene had no impact on any structural or estimated 
material properties in the vertebra.
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Bone Material Properties
Based on nanoindentation and AFM indentation, CKD-vehicle animals had 
indistinguishable material properties from the normal controls (Table 5). Raloxifene 
treatment resulted in harder skeletal tissue (assessed by nanoindentation) compared to both 
normal and CKD-vehicle animals (Table 5). Tissue composition (assessed by Raman 
spectroscopy) and collagen crosslinking (assessed by HPLC) revealed no differences among 
the three groups (Table 6). Collagen D-periodic spacing was not affected by CKD, but 
animals treated with raloxifene had higher D-periodicity in the collagen fibrils compared to 
CKD animals (Figure 4). NMR spectroscopic measures revealed no differences among 
groups for bound or free water (Table 6).
DISCUSSION
This experiment shows that in the setting of progressive CKD with high bone turnover, 
raloxifene treatment leads to lower tibial and vertebral trabecular bone remodeling. More 
importantly, energy to fracture and the modulus of toughness at the femoral diaphysis were 
higher in animals treated with raloxifene than their CKD counterparts. Nanoindentation also 
revealed that raloxifene treatment led to substantially harder cortical bone, while AFM 
imaging of collagen D-periodic spacing detected raloxifene-specific effects. Collectively, 
these data demonstrate that raloxifene can benefit skeletal material properties (those 
independent of bone mass) as well as structural properties and that together these ameliorate 
some of the CKD-associated deficits in whole bone mechanical properties.
Animals with CKD had substantially higher bone formation rates than their normal 
counterparts, indicating that untreated CKD animals have high turnover bone disease. 
Raloxifene effectively suppressed the high turnover induced by CKD to the level that was 
not significantly different than normal animals. While consistent with clinical data in 
postmenopausal women [17], this normalization of bone remodeling is in contrast to 
previous work in the same model using bisphosphonates and calcium, both of which 
suppressed remodeling in trabecular bone to well below normal levels [18–19]. Due to 
concerns over the dramatic suppression of bone remodeling in patients with CKD, the level 
of suppression observed with raloxifene may be advantageous. On the other hand, osteoclast 
number and percent osteoclast surface remained high in tibial trabecular bone with 
raloxifene treatment. This lack of effect on osteoclasts is consistent with biopsy data from 
postmenopausal women treated with raloxifene for two years [17]. Although raloxifene is 
typically associated with suppressed osteoclast formation, reduced osteoclast activity 
without a reduction in number has been described in other studies as well [20–21]. In this 
model of hyperparathyroidism, high levels of PTH may actually overshadow raloxifene’s 
effect on osteoclast formation, making its effect on the activity of mature osteoclasts more 
pronounced.
Untreated CKD animals had compromised mechanical properties of the long bones, 
consistent with previous studies in this model [18,22]. Raloxifene normalized energy to 
fracture, restoring it to the level of normal animals. Estimated material properties indicate 
that raloxifene specifically improved material-level toughness. These effects were absent in 
the vertebra. Because vertebral compression testing ceases at the ultimate load, information 
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regarding effects on whole bone and material-level toughness are limited, likely the reason 
for the no effect on these properties. Nevertheless, the positive effects of raloxifene on long 
bone mechanical properties represent the first study in this animal model in which a 
treatment has returned bone properties to normal levels in the absence of other adverse 
effects.
Though bone material properties can be estimated from whole bone mechanical tests, more 
direct assessments of cortical bone material properties were conducted at various length 
scales to better understand what aspects of bone quality raloxifene impacted in CKD bone. 
Unlike previous studies examining cortical bone mechanics in these animals [23], changes in 
material properties due to CKD were not apparent in this study. These data also contrast 
with changes in elastic modulus and hardness observed in the trabecular bone of patients 
with high turnover CKD [24]. However, because rodents do not display intracortical 
remodeling, high turnover is primarily a trabecular phenomenon in rodent models of CKD. 
Despite no obvious changes in cortical bone material properties in this study, raloxifene still 
had positive effects on hardness as measured by nanoindentation. Previous studies in murine 
and ovine ovariectomy models have also shown raloxifene-induced improvements in 
hardness [25–26]. While it is not clear how improving material-level hardness influences the 
modulus of toughness and energy to fracture, these results have been observed several times 
in animals treated with raloxifene [8–9,11,25–26].
Among the various components of bone quality, changes in hydration have been established 
as having significant effects on the mechanical properties of bone [27]. Previous studies 
have revealed that raloxifene improvements in material properties are associated with higher 
bound water in the extracellular matrix [11–12]. The current NMR data are inconsistent with 
these previous data because they revealed no effect on bound water in raloxifene-treated 
animals. The reason for this discrepancy is unclear. For example, CKD-associated changes 
in bone metabolism may prevent raloxifene from impacting bound water in these animals. 
Differences in animal models (dogs were used in previous studies) may be a factor as well. 
These differences may also reflect variations in the magnetic resonance techniques 
employed across these studies [11–12].
Rather than changes in hydration, the current work showed that raloxifene increased 
collagen fibril spacing (D-periodicity). Changes in collagen structure have been linked to 
altered bone mechanical properties [28]. Though the exact contribution of D-periodicity to 
whole bone mechanical properties remains unclear, this effect is consistent with previous 
work using raloxifene [11]. Previous studies have shown decreased D-periodic spacing in 
animals with reduced energy to fracture [29–30]. Hence, this work improves the current 
understanding of D-periodicity by showing that increases in D-periodicity are associated 
with improved bone toughness.
Consistent with our previous studies [18,22,31], animals with CKD had drastically higher 
levels of PTH than their normal counterparts. This occurred in the presence of normal 
calcium and phosphorus levels. Though Cy/+ rats eventually become hypocalcemic and 
hyperphosphatemic [18,31], the animals in this study only displayed the earlier rise in PTH 
observed in late stage CKD [2]. While no significant treatment effects were noted, trends 
Newman et al. Page 5
Kidney Int. Author manuscript; available in PMC 2016 July 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
were observed towards higher PTH and lower FGF23. While raloxifene’s impact on PTH 
may have affected bone outcomes, specific details regarding its mechanism cannot be 
determined from the current work. Unfortunately, the current literature has provided mixed 
results regarding the relationship between raloxifene and estrogen on serum PTH in the 
setting of hyperparathyroidism [32–37]. Clearly, more work is necessary to understand the 
interplay between raloxifene and serum biochemistry in the setting of CKD-MBD.
Most clinical data examining raloxifene’s use in CKD are derived from secondary 
assessments of large clinical trials, where they retrospectively examined patients with mild 
CKD [38]. Like their osteoporosis counterparts, CKD patients treated with raloxifene had a 
lower rate of vertebral fractures as well as increased BMD at the hip and spine. Far fewer 
data exist for patients with late stage disease due to their exclusion from osteoporosis trials. 
One small study examined BMD in patients on dialysis and showed that raloxifene improved 
BMD in the spine but not in the hip [16]. Another study examined BMD at the distal radius 
and found that raloxifene improved BMD in patients with mild hyperparathyroidism [33]. 
Despite these data, there have been no assessments of fracture efficacy using raloxifene in 
CKD. Because the current study suggests significant mechanical benefits despite modest 
changes in bone mass, the positive effects of raloxifene may be overlooked if BMD alone is 
used to determine efficacy.
Hesitation exists about raloxifene’s use in CKD mainly because of concerns about the 
increased risk of thromboembolism [4]. Post-hoc analyses of clinical CKD data with 
raloxifene show that the risk was not worse than the general population [13]. Previous 
guidelines have actually highlighted the need for further research using raloxifene in CKD, 
encouraging clinical trials examining safety and efficacy outcomes (including fracture 
incidence and vascular calcifications) [3]. The current results support those 
recommendations prior to the broad translation of this drug into clinical practice. Such 
studies will need to be undertaken in both sexes to ensure that our results in male Cy/+ rats 
translate to both males and females with CKD. Most importantly, such studies must include 
assessments beyond BMD in order to truly assess its efficacy in these patients. Recent 
techniques assessing bone quality have been developed for and examined in humans 
(ultrashort echo time magnetic resonance imaging [39] and reference point indentation [40–
41]). These, alongside BMD, may provide a better picture of the potential efficacy of 
raloxifene in patients with advanced kidney disease.
In light of these benefits, a few limitations must be acknowledged. The current duration of 
treatment approximated only one remodeling cycle in rats. Hence, the long-term effects of 
raloxifene in this model are unknown. Also, Cy/+ rats provide a model of high turnover 
CKD and may not translate to models of low turnover bone disease. Finally, because rodents 
do not undergo intracortical remodeling, future work will need to assess the mechanical 
benefits of raloxifene in an animal model of CKD with intracortical remodeling.
In summary, the current study shows that CKD rats treated with raloxifene had lower bone 
turnover and superior whole bone mechanical properties than their vehicle-treated 
counterparts. These beneficial effects on whole bone properties appear to be due to localized 
material property improvements. Because these changes occurred mostly independently of 
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changes in bone mass, traditional methods to evaluate efficacy in CKD bone disease may be 
insufficient for the evaluation of raloxifene in these patients.
METHODS
Animal Model
Cy/+ rats are characterized by autosomal dominant cystic disease [42]. These animals have a 
mutation (R823W) in Anks6, a gene that codes for the protein SamCystin. The function of 
this protein is unknown [43], but unlike many other cyst-related proteins, SamCystin does 
not localize to the primary cilia of kidney cells [44]. Recently, this gene was shown to be 
responsible for nephronophthisis in humans [45]. In this rat model, the mutation leads to a 
slow and gradual onset of CKD [42]. It parallels the human condition through the gradual 
development of abnormal mineral homeostasis and vascular calcification. Blood urea 
nitrogen (BUN) and creatinine are elevated by 25 weeks of age. At 30 weeks, kidney 
function is about 25% of that observed in normal animals, leading to progressive 
hyperphosphatemia, hyperparathyroidism, and skeletal abnormalities.
Experimental Design
Male Cy/+ rats were identified as in previous studies using this model [46–47]. Their normal 
littermates (n=8) served as controls. At 24 weeks, animals were placed on a casein diet 
(Purina AIN-76A; 0.7% Pi, 0.6% Ca) to increase phosphorus availability. This diet has been 
shown to produce a more consistent kidney disease phenotype [42].
Starting at 25 weeks of age, Cy/+ rats were treated with vehicle (n=9) or raloxifene (n=10) 
(1 mg/kg daily; subcutaneous) for 5 weeks. This treatment duration was chosen as it 
approximates an average bone remodeling cycle in skeletally mature rats (roughly six 
months in humans) and has been shown to be sufficient to detect treatment-induced skeletal 
changes in this model [18,22]. Raloxifene doses were based upon previous studies in 
ovariectomized female rats [10]. All rats were injected with calcein (10 mg/kg; 
subcutaneous) 14 and 4 days prior to sacrifice to label surfaces with actively forming bone.
At 30 weeks of age, animals were anesthetized with isoflurane and underwent cardiac 
puncture for blood draw followed by exsanguination and bilateral pneumothorax to ensure 
death. The lumbar spine, tibiae, and femora were removed and stored at −20°C for analysis. 
All procedures were approved by and carried out according to the rules and regulations of 
the Indiana University School of Medicine’s Institutional Animal Care and Use Committee.
Biochemistry
Blood plasma at 30 weeks was analyzed for BUN, calcium, and phosphorus using 
colorimetric assays (Point Scientific, Canton, MI, or Sigma kits). Intact PTH was determined 
by ELISA (Alpco, Salem, NH), which had an intra-assay CV of 4.8% and an inter-assay CV 
of 3.2%. FGF23 was assessed with a two-site assay (Immunotopics, San Clemente, CA) 
[18,31].
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Micro-Computed Tomography (microCT)
Using microCT (Skyscan 1172), trabecular bone volume (BV/TV, %) and architecture 
(number, spacing, and thickness) were determined from trabecular bone isolated from the 
metaphysis of the proximal tibia and the entire L4 vertebra. Cortical bone geometry (area, 
thickness, bending moments of inertia, and porosity) was determined from the femoral 
midshaft. Cortical thickness was assessed at 75% of the height of the vertebra (from cranial 
to caudal) because this represents a region free of zygapophyseal attachment. All bones were 
wrapped in parafilm to prevent drying and scanned at a resolution of 12 μm in accordance 
with standard guidelines [48].
Histomorphometry
Static and dynamic histomorphometric measures were obtained from the proximal 
metaphysis of the left tibia and the caudal metaphysis of the L3 vertebra. Histological 
processing followed previously used protocols [49–51]. Tissues were embedded in methyl 
methacrylate for undecalcified sections. Mid-transverse sections (4 μm) of cancellous bone 
from the proximal tibia and the caudal portion of the L3 vertebra were cut and left unstained 
for dynamic histomorphometry or stained with tartrate-resistant acid phosphatase (TRAP) 
for osteoclast measurements (tibia only). For tibial and vertebral cancellous bone, a region of 
interest (encompassing 7–8 mm2 and 1.5–2.0 mm2, respectively) approximately 0.8 mm 
from the growth plate was analyzed. The unstained sections were assessed for total bone 
surface, single-labeled surface, and double-labeled surface to calculate mineral apposition 
rate (MAR), percent mineralizing surface (MS/BS), and bone formation rate (BFR/BS). 
Because previous work in this model displayed no change in osteoid with disease, those 
measures were not conducted in this experiment. TRAP-stained sections were assessed for 
bone surface, osteoclast number, and osteoclast surface to calculate the number of 
osteoclasts per unit bone surface (N.Oc/BS) and percent osteoclast surface (Oc.S/BS). All 
histomorphometric nomenclature follows standard usage [52]. Six samples (two from each 
group) contained no double label and were excluded from MAR and BFR/BS calculations.
Whole Bone Mechanics
Structural mechanical properties of the left femur were determined by four-point bending. 
The anterior surface was placed on two lower supports located ±9 mm from the mid-
diaphysis (18 mm span length) with an upper span length of 6 mm. Specimens were loaded 
to failure at a rate of 2 mm/min, producing a force-displacement curve for each sample. 
Structural mechanical properties (ultimate force, stiffness, energy to fracture, total 
displacement) were obtained directly from these curves, while apparent material properties 
(ultimate stress, elastic modulus, toughness) were derived from the force-displacement 
curves, cross-sectional moments of inertia (Iml), and the distances from the centroid to the 
tensile surface using standard beam-bending equations for four-point bending [53].
Structural mechanical properties of the L4 vertebra were determined by uniaxial 
compression. Vertebra height was assessed from microCT images. Prior to mechanical 
testing, the vertebral arch and endplates were removed using an Isomet saw to create parallel 
surfaces (inside the growth plates) for compression testing. One untreated CKD sample was 
damaged during processing and thus not used for testing. Specimens were loaded at a rate of 
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0.5 mm/min, producing a force-displacement curve for each sample. Structural mechanical 
properties were obtained directly from these curves, while apparent material properties were 
derived from the force-displacement curves, pre-test sample heights, and the average bone 
area of five microCT slices (10%, 30%, 50%, 70%, and 90% slices of the pre-test sample 
height) using standard equations for uniaxial compression [54–55].
Tissue Composition
The anteromedial portion of the right tibial mid-diaphysis was polished with a 0.05 μm 
alumina suspension in order to create a flat region for spectroscopy and subsequent 
indentation testing. Raman spectroscopy was performed using a LabRAM HR 800 Raman 
Spectrometer (HORIBA JobinYvon, Edison, NJ) connected to a BX41 microscope 
(Olympus, Tokyo, Japan). A 660 nm laser was focused on the bone surface using a 50X 
objective to a spot size of ~10 μm. Three locations were imaged ~3 mm apart on the 
polished surface with five 20 second acquisitions at each location as previously published 
[56]. A five-point linear baseline correction was applied in LabSpec 5 (HORIBA 
JobinYvon). Using OriginPro 8.6 (OriginLab, Northampton, MA), a single Gaussian peak 
was fit to the PO43−ν1 peak, and the areas under the PO43−ν1 (930–980 cm−1), CO32−ν1 
(1056–1091 cm−1), and Amide I (1551–1720 cm−1) bands were calculated at each location. 
Type B carbonate substitution was found by the band area ratio of CO32−ν1/PO43−ν1. The 
degree of matrix mineralization was determined by the band area ratio of PO43−ν1/Amide I. 
Mineral maturity (crystallinity) was determined by the inverse of the full width at half 
maximum (FWHM) of the PO43−ν1 peak.
AFM Indentation
Using the polished tibial surface described above, indentations were performed using a 
BioScope Catalyst atomic force microscope (Bruker, Santa Barbara, CA), operating in peak 
force tapping mode using previously published methods [57]. Samples were partially 
submerged in ultrapure water with the surface remaining uncovered for optical imaging of 
the surface in order to determine indentation locations but then fully submerged during 
testing. Indentations were performed using a tungsten carbide-coated AFM probe (Nanotec; 
nominal tip radius of 60 nm) with a nominal spring constant of 650 N/m. Three locations 
(co-localized with Raman measurements) per sample were indented, and at each location (20 
μm×20 μm grid), 100 indentations were performed. Samples were loaded to 3.25 μN with 
force-separation curves acquired from each indentation. Within each location, indentations 
were spaced about 2 μm apart in order to avoid interactions from neighboring indentations. 
In total, 300 indentations were performed for each sample. The indentation elastic modulus 
was calculated from 20% to 80% of the withdrawal curve using the Sneddon model of 
contact between a rigid cone and an elastic half space because the indentation depth is 
greater than the radius of curvature of the probe [57]. Only those indentations whose 
retraction curve produced an r2 value of 0.90 or higher were included in the analysis (n=6–
95 per location). The indentation elastic modulus was determined from the following 
equation:
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where F is the indentation force, ES is the indentation elastic modulus of the sample, νS is 
the Poisson’s ratio of the sample (assumed to be 0.35), α is the opening angle (assumed to 
be 20°), and δ is the indentation depth. All of the individual indentations were averaged to 
produce a single value for each location, and each of these locations was averaged to 
produce a single value for each sample.
Nanoindentation
After AFM indentation, nanoindentation was performed on the same tibial samples using a 
Hysitron TI950 TriboIndenter. As above, samples were partially submerged in ultrapure 
water with the surface remaining uncovered for optical imaging of the surface in order to 
determine indentation locations but then fully submerged during testing. Three locations (co-
localized with AFM indentations) per sample were indented. Pre-saved test locations were 
imaged using the nanoindenter for in situ scanning probe imaging. Within this imaged 
region, 6 indentations were performed on a 10 μm × 20 μm grid. Indentations were spaced 
10 μm apart in order to avoid interactions from neighboring indentations. A previously 
calibrated fluid cell Berkovich diamond probe was used for the indentations. Machine 
calibrations were performed at the beginning of each day of testing. Tests were conducted in 
load control, and the loading profile consisted of a 10s loading period, a 10s hold at 3000 
μN, and a 10 s unloading period. From the resulting load-displacement profiles, the 
indentation elastic modulus and hardness were calculated according to the following 
equations:
where Er is the reduced indentation elastic modulus of the sample, A is contact area, hc is the 
contact displacement, S is the stiffness of the sample determined from 40–95% of the 
unloading slope, H is the hardness of the sample, and Pmax is the peak force. All of the 
individual indentations (n=6 per location) were averaged to produce a single value for each 
location, and each of these locations was averaged to produce a single value for each sample.
Collagen Morphology
Following indentation testing, the polished tibial surface was partially decalcified by soaking 
the bones in 0.5 M EDTA for 25 minutes followed by five minutes of sonication in a water 
bath. This process was repeated five times for each sample. For imaging, RTESPA probes 
were used (Bruker; nominal radius of 8 nm; spring constant = 40 N/m). For measurements 
of collagen morphology, the scan size was set at 3.5 μm with 512×512 pixels and a scan rate 
of 0.5 lines/s. Two locations between indentation sites were imaged per sample (one location 
was dropped from a raloxifene sample due to poor image quality), and 12 fibrils were 
measured at each location. All 24 fibrils were averaged to produce a single value for each 
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animal (one normal sample had only 18 fibrils and two CKD samples had 14 and 20 fibrils 
due to poor image quality). Using SPIP 5.1.10 (Image Metrology, Hørsholm, Denmark), D-
periodic spacing was calculated using 2D Fast Fourier Transformations as previously 
described [57].
Collagen Cross-Linking
After four-point bending, proximal segments of the left femoral cortex (~3 mm in length) 
were fully demineralized in 20% EDTA (0.68 M, pH 7.4). Approximately 10 mg of 
demineralized bone were hydrolyzed in 6N HCl (~10 μL per 1 mg) at 110°C for 20–24 
hours. After evaporating the acid using a SpeedVAC centrifuge with a cold trap, each 
hydrolysate was resuspended in ultrapure water, split into two equal portions, and dried. Half 
of the residue was resuspended in ultrapure water with an internal standard (5×10−6 g/L 
pyridoxine). The solution was filtered and diluted with 0.05% heptafluorobutyric acid in 
10% acetonitrile, and 50 μL of each hydrolysate were assayed by a high performance liquid 
chromatography (HPLC) system (Beckman-Coulter System Gold 168) with a silica-based 
column (Waters Spherisorb) as previously published [58]. Standards with varying 
concentrations of pyridinoline (PYD; Quidel), deoxypyridinoline (DPD; Quidel), 
pentosidine (PE; International Maillard Reaction Society), and a constant amount of 
pyridoxine were also assayed. Using a Waters 2475 fluorescence detector (excitation/
emission of 295/400 nm for PYD and DPD and 328/378 nm for PE), chromatograms were 
recorded to determine the amount of each crosslink. These amounts were then normalized 
by collagen content, which was determined from the other half of each hydrolysate by 
another HPLC assay. With α-amino-butyric acid (α-ABA) included as an internal standard, 
the amino acids were subjected to derivatization with phenyl isothiocyanate (PITC). Along 
with varying concentrations of derivatized hydroxyproline (Sigma) and a constant amount of 
α-ABA as standards, the derivatized samples were resuspended in a buffer solution of 5% 
acetonitrile in 5 mM disodium phosphate. Upon injecting 50 μL of this sample, 
chromatograms were generated with a UV detector (Beckman-Coulter System Gold 168). 
The calculated mass of hydroxyproline was then multiplied by 7.5 (assuming 13–14% of 
type I collagen by mass) and divided by the molecular weight of collagen (30,000 Da), 
thereby giving crosslink concentration as mol/mol of collagen.
1H Nuclear Magnetic Resonance Spectroscopy
A ~5-mm cross-section of the left femoral mid-shaft was placed into a low proton, loop-gap-
style radio-frequency (RF) coil along with a reference microsphere of water (T2~2 s). As 
previously published [58], the nuclear magnetic resonance spectroscopy (NMR) analysis 
was performed in a 4.7-T horizontal-bore magnet (Varian Medical Systems, Santa Clara, 
CA) using 90°/180° RF pulses of ~9/18-μs duration and collecting Carr-Purcell-Meiboom-
Gill (CPMG) measurements with 10,000 echoes at 100 μs spacing in order to separate 
proton signals within the bone. To generate the spectrum of transverse relaxation time 
constants (T2), the echo magnitudes were fitted with multiple exponential decay functions. 
Upon normalizing the integrated areas of bound water (T2=1200–800 μs) and pore water 
(T2=800 μs –600 ms) to the area of the reference (T2=600 ms–10 s), the volume of bound 
water and the volume of pore water were divided by the specimen volume (calculated using 
Archimedes’ principle) to give bound water (bw) and pore water (pw) volume fractions.
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Statistics
Comparisons among groups were assessed by one-way ANOVA with Fisher’s LSD post-hoc 
tests. For parameters with non-normal distributions (assessed by Shapiro-Wilk tests), 
comparisons among groups were made by Kruskal-Wallis tests with Mann-Whitney U post-
hoc tests (using a Bonferroni correction). The specific test used for each variable is noted in 
the figures/tables. A priori α-levels were set at 0.05 to determine significance. Data are 
presented as mean ± standard deviation.
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Figure 1. 
Cancellous bone structure in the proximal tibia and lumbar vertebra as determined by 
microCT. *, p<0.05 compared to NL; #, p<0.05 compared to CKD-VEH
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Figure 2. 
Bone formation rates in the proximal tibia and caudal lumbar vertebra as determined by 
dynamic histomorphometry. *, p<0.05 compared to NL; #, p<0.05 compared to CKD-VEH
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Figure 3. 
Structural and apparent material properties of the femur as determined by four-point 
bending: (a) ultimate load, (b) energy to fracture, (c) ultimate stress, and (d) modulus of 
toughness. *, p<0.05 compared to NL; #, p<0.05 compared to CKD-VEH
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Figure 4. 
Collagen fibril D-periodic spacing as determined by AFM imaging. #, p<0.05 compared to 
CKD-VEH
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Table 1
Biochemistry
Biochemistry Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
BUN (mg/dL)§ 14.62 ± 1.95 48.32 ± 8.20 * 44.12 ± 5.12 *
Calcium (mg/dL)§ 9.979 ± 0.987 11.610 ± 2.323 10.061 ± 2.421
Phosphorus (mg/dL)§ 4.527 ± 0.579 6.682 ± 2.408 * 9.700 ± 3.591 *
PTH (pg/mL)¶ 181.97 ± 105.05 2194.39 ± 1811.01 * 1257.46 ± 1456.22 *
FGF23 (pg/mL)§ 698.36 ± 93.03 2556.83 ± 1401.96 * 6184.88 ± 3403.39 *
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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Table 2
MicroCT
Proximal Tibia Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
BV/TV (%)§ 17.04 ± 3.34 11.26 ± 1.51 * 14.9 ± 2.70 #
Tb.Th (mm)¶ 0.106 ± 0.010 0.108 ± 0.004 0.103 ± 0.007
Tb.N (1/mm)§ 1.611 ± 0.253 1.052 ± 0.150 * 1.451 ± 0.211 #
Tb.Sp (mm)§ 0.369 ± 0.044 0.604 ± 0.114 * 0.420 ± 0.055 #
Femoral Diaphysis Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Ct.Th (mm)§ 0.876 ± 0.037 0.748 ± 0.056 * 0.783 ± 0.039 *
Ct.Ar (mm2)¶ 8.767 ± 0.631 7.324 ± 0.358 * 7.611 ± 0.397 *
Iap (mm4)¶ 15.00 ± 2.59 12.40 ± 0.58 * 12.30 ± 1.35 *
Iml (mm4)¶ 10.23 ± 1.56 7.50 ± 0.59 * 7.86 ± 0.73 *
Ct.Po (%)¶ 0.690 ± 0.324 0.948 ± 0.401 0.467 ± 0.274 #
Lumbar Vertebra Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
BV/TV (%)§ 41.88 ± 2.92 30.01 ± 3.98 * 36.27 ± 1.76 *#
Tb.Th (mm)¶ 0.119 ± 0.004 0.110 ± 0.007 * 0.108 ± 0.005 *
Tb.N (1/mm)§ 3.581 ± 0.258 2.726 ± 0.324 * 3.401 ± 0.129 #
Tb.Sp (mm)§ 0.213 ± 0.021 0.280 ± 0.031 * 0.235 ± 0.014 * #
Ct.Th (mm)¶ 0.236 ± 0.033 0.170 ± 0.012 * 0.184 ± 0.025 *
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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Table 3
Histomorphometry
Tibia Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
MAR (μm/day)¶ 1.305 ± 0.185 2.470 ± 0.569 1.890 ± 0.511
MS/BS (%)§ 26.56 ± 5.14 33.32 ± 4.11 23.89 ± 4.75 #
BFR/BS (μm3/μm2/year)¶ 126.65 ± 31.02 299.62 ± 74.35 * 170.40 ± 78.52 #
Oc.S/BS (%)¶ 7.157 ± 1.250 15.739 ± 3.332 * 15.684 ± 6.857 *
N.Oc/BS (1/mm)§ 1.966 ± 0.412 4.125 ± 0.785 * 4.134 ± 1.653 *
Vertebra Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
MAR (μm/day)¶ 1.057 ± 0.339 1.983 ± 0.876 1.574 ± 0.400
MS/BS (%)§ 13.62 ± 3.98 27.81 ± 5.73 * 16.21 ± 3.73 #
BFR/BS (μm3/μm2/year)¶ 52.14 ± 21.76 211.94 ± 128.49 * 94.19 ± 39.80 #
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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Table 4
Whole Bone Mechanics
Femur Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Ultimate Force (N)§ 272.08 ± 17.75 204.81 ± 23.20 * 223.44 ± 23.78 * #
Stiffness (N/mm)¶ 531.67 ± 47.41 412.96 ± 56.28 * 440.66 ± 30.52 *
Energy to Fracture (mJ)§ 119.16 ± 15.33 91.65 ± 14.13 * 107.24 ± 20.86 #
Total Displacement (mm)§ 781.56 ± 53.46 745.15 ± 67.76 825.01 ± 95.15
Ultimate Stress (MPa)§ 153.81 ± 15.68 143.94 ± 17.93 146.76 ± 13.28
Elastic Modulus (MPa)§ 4.649 ± 0.633 5.144 ± 0.971 4.998 ± 0.466
Toughness (MPa)§ 4.336 ± 0.382 3.652 ± 0.545 * 4.096 ± 0.814 #
Total Strain (mε)§ 50.44 ± 4.48 42.74 ± 4.23 * 47.73 ± 4.97
Mechanics (Vertebra) Normal (n=8) CKD (Vehicle) (n=8) CKD (Raloxifene) (n=10)
Ultimate Force (N)§ 256.89 ± 60.01 187.06 ± 48.03 * 179.57 ± 38.63 *
Stiffness (N/mm)§ 952.09 ± 314.20 866.74 ± 260.33 854.76 ± 277.85
Energy (mJ)§ 46.27 ± 10.60 28.05 ± 8.93 * 26.46 ± 7.33 *
Total Displacement (mm)§ 0.445 ± 0.123 0.355 ± 0.062 0.399 ± 0.97
Ultimate Stress (MPa)§ 42.49 ± 10.00 38.74 ± 9.16 34.16 ± 7.89
Elastic Modulus (MPa)§ 954.37 ± 334.35 1174.00 ± 447.08 1124.68 ± 372.23
Toughness (MPa)§ 1.310 ± 0.470 0.924 ± 0.347 0.714 ± 0.135
Total Strain (mε)§ 73.84 ± 25.98 58.37 ± 13.51 57.27 ± 12.07
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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Table 5
Material Properties – Mechanics
Nanoindentation Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Elastic Modulus (GPa)§ 11.066 ± 2.766 9.666 ± 1.021 13.200 ± 3.345
Hardness (MPa)¶ 202.62 ± 22.86 192.68 ± 47.35 422.81 ± 291.97 #
AFM Indentation Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Elastic Modulus (GPa)§ 52.99 ± 25.81 43.21 ± 16.31 49.25 ± 26.20
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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Table 6
Material Properties – Composition and Morphology
Raman Spectroscopy Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Crystallinity (1/FWHM PO43−ν1)§ 0.0529 ± 0.0003 0.0534 ± 0.0008 0.0535 ± 0.0005
Carbonate Substitution (CO32−ν1/PO43−ν1)§ 0.247 ± 0.008 0.242 ± 0.013 0.239 ± 0.015
Relative Mineralization (PO43−ν1/Amide I)§ 2.650 ± 0.332 2.274 ± 0.501 2.384 ± .0422
Collagen Morphology Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
D-Periodicity (nm)§ 65.321 ± 0.946 64.466 ± 1.391 65.438 ± 1.289 #
Collagen Cross-Linking Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Pyridinoline per Collagen (mol/mol)§ 0.474 ± 0.485 0.223 ± 0.087 0..305 ± 0.079
Deoxypyridinoline per Collagen (mol/mol)§ 0.372 ± 0.388 0.203 ± 0.095 0.271 ± 0.088
Pentosidine per Collagen (mmol/mol)§ 815.39 ± 621.34 507.06 ± 288.11 617.48 ± 171.46
NMR Spectroscopy Normal (n=8) CKD (Vehicle) (n=9) CKD (Raloxifene) (n=10)
Bound Water (%)¶ 18.60 ± 3.61 17.88 ± 4.00 17.34 ± 3.43
Pore Water (%)§ 3.829 ± 0.988 5.572 ± 3.567 4.158 ± 0.965
§One-Way ANOVA followed by Fisher’s LSD tests
¶
Kruskal-Wallis test followed Mann-Whitney U tests (with Bonferroni correction)
*
vs. Normal
#
vs. CKD (Vehicle)
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